Samsung BioLogics says no decision yet on producing Moderna's Covid-19 shot

Samsung BioLogics says no decision yet on producing Moderna's Covid-19 shot
Samsung BioLogics says no decision yet on producing Moderna's Covid-19 shot

Hello and welcome to the details of Samsung BioLogics says no decision yet on producing Moderna's Covid-19 shot and now with the details

Nevin Al Sukari - Sana'a - The Moderna shot has yet to be approved in South Korea, but the second of three expert panels recommended approval for emergency use of the vaccine yesterday, based on its safety and efficacy in Phase 3 late-stage trials in the United States. — Reuters pic

Subscribe to our Telegram channel for the latest updates on news you need to know.


SEOUL, May 14 ― Samsung BioLogics Co Ltd said today that no decision has been made yet on producing Moderna Inc's Covid-19 vaccine in South Korea after a local newspaper reported the two companies had agreed on a contract manufacturing deal.

The Chosun Ilbo reported that the biotech arm of Samsung Group has agreed to produce the Moderna vaccine in its plant in Songdo, part of which will be used for domestic vaccination, citing unnamed government and pharmaceutical industry sources.

Samsung BioLogics said in a filing to the stock exchange that it could confirm the report as no decision has been finalised. The decision will be made within a one-month time frame, a company official told Reuters by phone.

Moderna was not immediately available for comment.

Samsung BioLogics' shares today rose as much as 4.9 per cent to 908,000 won (RM3,317.58) in morning trade, versus the broader market KOSPI's 0.7 per cent rise.

The statement follows a denial by Samsung and Pfizer Inc earlier this week of another media report that the two companies were working together to produce a Covid-19 vaccine developed by the US firm and its German partner BioNTech .

The Moderna shot has yet to be approved in South Korea, but the second of three expert panels recommended approval for emergency use of the vaccine yesterday, based on its safety and efficacy in Phase 3 late-stage trials in the United States.

South Korea has reported 747 new Covid-19 cases yesterday, bringing the total number of confirmed cases to 130,380, with death toll of 1,893.

Just over 7 per cent of the country's population have received at least one dose of AstraZeneca Plc or Pfizer vaccine, as it aims to vaccinate over 70 per cent of the residents by September and attain herd immunity by November. ― Reuters

These were the details of the news Samsung BioLogics says no decision yet on producing Moderna's Covid-19 shot for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.

It is also worth noting that the original news has been published and is available at Malay Mail and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.

PREV Thailand to narrow gap for AstraZeneca shots in bid to curb Delta variant
NEXT Alpha, Beta, Gamma, Delta — WHO uses Greek alphabet to name COVID-19 variants